Utah Cancer Specialists Cancer Center
Welcome,         Profile    Billing    Logout  
 1 Trial 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kendall, S DiSean
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
NCT05249101: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Recruiting
1/2
70
US
Ivaltinostat, Capecitabine, Xeloda
CG Pharmaceuticals, Inc
Metastatic Pancreatic Adenocarcinoma
02/26
06/26
Kendall, Stephan
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
NCT05588609: Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Active, not recruiting
2
90
US
Afatinib Oral Tablet, GILOTRIF®, GIOTRIF®, Enzalutamide Pill, XTANDI®, Abiraterone acetate tablets, ZYTIGA®, MCLA-128, Zenocutuzumab
Merus N.V.
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
10/25
03/26
MCLA-158-CL01, NCT03526835 / 2017-004745-24: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Recruiting
1/2
523
Europe, US
MCLA-158, petosemtamab, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Merus N.V., Merus N.V.
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
11/25
11/27
NCT04657068: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting
1/2
547
Europe, US
ART0380, Gemcitabine, Gemzar, Irinotecan, Camptosar, Camptothecin-11
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
06/25
NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting
1
82
US
VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
VM Oncology, LLC
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
07/26
12/26
NCT04507503: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing
N/A
US
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma
 
 

Download Options